Landscape analysis and oncologic outcomes in advanced urothelial carcinoma by NECTIN4 RNA expression


Tyler Stewart, Sarah Fenton, Shayan Nazari, Andrew Elliott, Rohan Garje, Amirali Salmasi, Aditya Bagrodia, Chadi Nabhan, David VanderWeele, Rana McKay


  • Advanced urothelial carcinoma (UC) is a devastating disease, however recent advances with antibody drug conjugates (ADCs), including enfortumab vedotin (EV), have improved outcomes significantly.1,2
  • Currently no biomarkers are clinically available to predict response to therapy EV.
  • We hypothesized that benefit from EV may correlate with RNA expression of NECTIN4, the gene encoding the relevant cell surface antigen for EV.
  • Therefore, we performed a landscape analysis of NECTIN4 in advanced UC and correlated expression with oncologic outcomes.
Download Publication